The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2024 | The importance of treating anemia early to avoid transfusion-dependence in LR-MDS
Matteo Della Porta, MD, IRCCS Humanitas Research Hospital, Milan, Italy, emphasizes the importance of treating anemia early before the need for regular transfusions in lower-risk myelodysplastic syndromes (LR-MDS). He notes that the history of erythropoiesis-stimulating agents (ESAs) shows better patient responses when treatment begins before anemia onset. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
